U.S. COMPANY FILING
JOHNSON & JOHNSON — Form 10-Q filed 2026-04-22
Filing text preview
J&J Q1 2026 sales rose 9.9% to $24.06B, but net earnings fell 52.4% to $5.24B due to prior-year other income. Diluted EPS was $2.14. The company plans to separate its Orthopaedics business within 18-24 months.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record